Anti-ACSL1 antibody produced in rabbit

ACSL1 (acyl-CoA synthetase long-chain family member 1) is the main isoform of the long-chain acyl coenzyme A (acyl-CoA) synthetase (ACSL) isoenzymes. It is predominantly expressed in tissues with high energy metabolism such as, fat, skeletal muscles and liver. This gene maps to human chromosome 4q34-q35.

Long-chain-fatty-acid--CoA ligase 1 recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

ACSL1 (acyl-CoA synthetase long-chain family member 1) is involved in the synthesis of triacylglycerols (TAG) and fatty acid metabolism. It activates and traps free fatty acids (FFAs) within cells. It catalyzes the conversion of FFAs to acyl coenzyme A (acyl-CoA) in the presence of ATP. It also has a role in heart metabolism. This gene has a putative role in determining endurance performance, and SNP rs6552828 is marginally linked with elite endurance performance in Chinese (Han) male population. However, no such association is found in Chinese female or Caucasian population. Polymorphism rs9997745 in ACSL1 is linked with the risk of metabolic syndrome. Eicosapentaenoic acid down-regulates the expression of this gene, which in turn leads to the down-regulation of palmitate-induced cytokine production. This results in the decrease of chronic inflammation in atherosclerotic plaques.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST71196

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.